Transgene (company)

Transgene S.A.
Company type	Public (S.A.)
Traded as	Euronext Paris: TNG
Industry	Biotechnology; Life science;
Founded	December 1979
Founders	Pierre Chambon; Philippe Kourilsky;
Headquarters	Illkirch-Graffenstaden, France
Key people	Hedi Ben Brahim (President and CEO)
Website	www.transgene.fr

Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, and develops and manufactures immunotherapies for the treatment of cancer.

The company has two technological platforms based on these respective approaches: myvac (therapeutic vaccines) and Invir.IO (oncolytic viruses). Transgene’s portfolio consists of four products currently in clinical development.

Since January 2021, Hedi Ben Brahim has served as President and Chief Executive Officer of Transgene SA. The company is listed on the Paris Stock Exchange.^[1]^[2]

^ "Transgene". Euronext Live markets.
^ "CureVac hires GSK Vaccines veteran Blanc as CBO and chief commercial officer; plus moves at Spero, 4D, Transgene, Achilles and Datavant". BioCentury. Retrieved 2021-09-26.

[1] "Transgene". Euronext Live markets.

[2] "CureVac hires GSK Vaccines veteran Blanc as CBO and chief commercial officer; plus moves at Spero, 4D, Transgene, Achilles and Datavant". BioCentury. Retrieved 2021-09-26.

[1]

[2]